Surfactant Safety in Newborns with Pneumothorax
Surfactant therapy is safe and should be administered to newborns with pneumothorax complicating respiratory distress syndrome, but only after the pneumothorax is adequately managed through drainage or stabilization. The key is proper sequencing: address the air leak first, then give surfactant to treat the underlying surfactant deficiency.
Evidence-Based Approach
Safety Profile from Guidelines
The 2014 AAP guidelines explicitly address this scenario. Surfactant administration in meconium aspiration syndrome (which shares similar air leak risks) did not increase the frequency of pneumothoraces or pulmonary interstitial emphysema 1. This demonstrates that surfactant itself does not inherently worsen air leaks when properly administered.
However, the guidelines emphasize a critical safety consideration: surfactant rapidly improves lung compliance, functional residual capacity, and lung volume 1. This means expeditious changes in mechanical ventilator settings are necessary immediately after administration to minimize risks of lung injury and further air leak 1.
Clinical Management Algorithm
Step 1: Stabilize the Pneumothorax
- If clinically significant pneumothorax is present, perform thoracentesis or chest tube insertion first
- Confirm adequate lung re-expansion before proceeding
Step 2: Administer Surfactant Using Appropriate Technique
- For infants with pre-existing pneumothorax, consider using a laryngeal mask airway (LMA) device to deliver surfactant without applying positive pressure ventilation, which could exacerbate the air leak 2
- In a 2025 case series, this LMA technique successfully avoided subsequent invasive ventilation and chest tube insertion in 13 of 20 neonates with pneumothorax complicating RDS, with no major complications 2
Step 3: Immediate Post-Surfactant Monitoring
- Rapidly adjust ventilator settings as lung compliance improves
- Monitor closely for signs of air leak expansion
- Ensure clinicians with expertise in surfactant administration are responsible for the procedure 1
Important Caveats
Timing matters critically. The evidence shows surfactant is beneficial when the underlying condition is RDS with secondary pneumothorax. The pneumothorax itself is not a contraindication—it's a complication that requires management before or concurrent with surfactant therapy.
Avoid positive pressure ventilation during administration when possible in the presence of active pneumothorax. The novel LMA technique provides a safer delivery method in this specific scenario 2.
Lung ultrasound guidance can help confirm pneumothorax resolution (absence of lung sliding, loss of B-lines, lung point sign) and underlying RDS patterns before surfactant administration 3. This real-time imaging allows precise timing of therapy.
Risk-Benefit Analysis
The benefits of surfactant in RDS—reduced mortality, decreased chronic lung disease, and improved oxygenation 1—far outweigh the theoretical risk of worsening pneumothorax when proper precautions are taken. The pneumothorax itself often results from the underlying surfactant deficiency and mechanical ventilation, so treating the root cause with surfactant actually reduces further air leak risk.
One case report documented a retained surfactant catheter with associated pneumothorax 4, but this represents a procedural complication rather than a contraindication to therapy itself.
Bottom Line
Surfactant is safe in newborns with pneumothorax when you: (1) manage the pneumothorax first through drainage, (2) use appropriate administration techniques like LMA to avoid excessive positive pressure, and (3) rapidly adjust ventilator settings post-administration 1, 2. The presence of pneumothorax should prompt careful technique, not avoidance of life-saving surfactant therapy.